Literature DB >> 1349438

Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse.

B Guardiola-Lemaître1, A Lenègre, R D Porsolt.   

Abstract

The effects of behaviorally nonactive doses of melatonin and diazepam were investigated in two test models for anxiolytics in mice to see whether mutual enhancement could be observed when the two treatments were combined. The test models used were the four plates test and the tail suspension test. In the former test anxiolytics increase the number of punished crossings and in the latter increase the duration of immobility of mice suspended by the tail. In the four plates test combined treatment with melatonin (128 and 256 mg/kg IP) and diazepam (0.5 mg/kg PO) caused a significant increase in the number of punished crossings, whereas each treatment alone was without effect. Similarly, in the tail suspension test, a clear increase in the duration of immobility was observed after combined treatment (256 mg/kg IP melatonin + 0.5 mg/kg PO diazepam), whereas no effects were observed with the individual treatments alone. These results suggest that melatonin can enhance the anxiolytic actions of diazepam.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349438     DOI: 10.1016/0091-3057(92)90118-y

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Melatonin Prevents the Harmful Effects of Obesity on the Brain, Including at the Behavioral Level.

Authors:  Adrian Rubio-González; Juan Carlos Bermejo-Millo; Beatriz de Luxán-Delgado; Yaiza Potes; Zulema Pérez-Martínez; José Antonio Boga; Ignacio Vega-Naredo; Beatriz Caballero; Juan José Solano; Ana Coto-Montes
Journal:  Mol Neurobiol       Date:  2017-10-30       Impact factor: 5.590

Review 2.  The rhythmic GABAergic system.

Authors:  D P Cardinali; D A Golombek
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  An endogenous 5-HT(7) receptor mediates pigment granule dispersion in Xenopus laevis melanophores.

Authors:  M T Teh; D Sugden
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  PK 11195 blockade of benzodiazepine-induced inhibition of forskolin-stimulated adenylate cyclase activity in the striatum.

Authors:  C C Tenn; J M Neu; L P Niles
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 5.  Efficacy and safety of supplemental melatonin for delayed sleep-wake phase disorder in children: an overview.

Authors:  David Mantle; Marcel Smits; Myrthe Boss; Irene Miedema; Inge van Geijlswijk
Journal:  Sleep Med X       Date:  2020-08-19

Review 6.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

Review 7.  Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders.

Authors:  Yong-Ku Kim; Sang Won Jeon
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

8.  Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.

Authors:  Mark J Millan; Mauricette Brocco; Alain Gobert; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2004-07-31       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.